PDF(Pubmed)
Abstract：
Obesity is a major health concern worldwide, and its prevalence continues to increase in several countries. Pyrroloquinoline quinone (PQQ) is naturally found in some foods and is available as a dietary supplement in its disodium crystal form. The potential health benefits of PQQ have been studied, considering its antioxidant and anti-inflammatory properties. Furthermore, PQQ has been demonstrated to significantly influence the functions of mitochondria, the organelles responsible for energy production within cells, and their dysfunction is associated with various health conditions, including obesity complications. Here, we explore PQQ properties that can be exploited in obesity treatment and highlight the underlying molecular mechanisms. We review animal and cell culture studies demonstrating that PQQ is beneficial for reducing the accumulation of visceral and hepatic fat. In addition to inhibiting lipogenesis, PQQ can increase mitochondria number and function, leading to improved lipid metabolism. Besides diet-induced obesity, PQQ ameliorates programing obesity of the offspring through maternal supplementation and alters gut microbiota, which reduces obesity risk. In obesity progression, PQQ mitigates mitochondrial dysfunction and obesity-associated inflammation, resulting in the amelioration of the progression of obesity co-morbidities, including non-alcoholic fatty liver disease, chronic kidney disease, and Type 2 diabetes. Overall, PQQ has great potential as an anti-obesity and preventive agent for obesity-related complications. Although human studies are still lacking, further investigations to address obesity and associated disorders are still warranted.
摘要：
肥胖是全球范围内的主要健康问题，在几个国家，其患病率继续增加。吡咯喹啉醌（PQQ）天然存在于某些食物中，并以其二钠晶体形式作为膳食补充剂。已经研究了PQQ的潜在健康益处，考虑到它的抗氧化和抗炎特性。此外，PQQ已被证明显著影响线粒体的功能，负责细胞内能量产生的细胞器，它们的功能障碍与各种健康状况有关，包括肥胖并发症.这里,我们探索了可用于肥胖治疗的PQQ特性,并强调了潜在的分子机制.我们回顾了动物和细胞培养研究，证明PQQ有利于减少内脏和肝脏脂肪的积累。除了抑制脂肪生成，PQQ可以增加线粒体数量和功能，导致改善脂质代谢。除了饮食引起的肥胖，PQQ通过补充母体来改善后代的程序化肥胖，并改变肠道微生物群，降低肥胖风险。在肥胖进展中，PQQ减轻线粒体功能障碍和肥胖相关炎症，改善了肥胖合并症的进展，包括非酒精性脂肪肝,慢性肾病,2型糖尿病。总的来说,PQQ作为抗肥胖和预防肥胖相关并发症的药物具有巨大的潜力。尽管人类研究仍然缺乏，针对肥胖和相关疾病的进一步研究仍有必要.
